3D Systems finds itself in a rare bind — a 64% price rally over the past month is colliding head-on with a short base that has grown, not retreated, in the same period.
Short positioning is the defining story here. Short interest has climbed to 31.6% of the free float, up from around 27% at the start of May and up again roughly 10% over just the past week. That week-on-week acceleration is notable: it points to fresh shorts being added into the rally, not covering. At 7.5 days to cover on FINRA's fortnightly count, any squeeze dynamic would take time to unwind. The ORTEX short score sits at 79.4 out of 100 — a firmly elevated reading that has barely moved in the past two weeks, suggesting the short thesis remains largely intact in the eyes of those holding it.
The borrow market tells a more nuanced story. Availability is currently around 109% — meaning there are roughly as many shares available to borrow as are already borrowed — so shorts are not yet under mechanical pressure to exit. That number has tightened from a peak of 165% in mid-May, a consistent drift toward a tighter pool, but it remains well above the 52-week low of just 0.27%, where the lending market was essentially shut. Cost to borrow has tripled over the week to 0.53% annualised, which sounds dramatic in percentage-change terms but is still negligible in absolute cost — there is no squeeze tax discouraging short-sellers. Options positioning leans in the same direction: the put/call ratio of 0.16 is near the bottom of its one-year range, a sign that options traders are positioned for further upside rather than protecting against a fall, which stands in contrast to the scale of the short book.
The Street offers thin cover for either camp. Coverage is sparse: Cantor Fitzgerald reiterated an Overweight with a $5 target in mid-May, which at least sits credibly above the current $3.88 price. Needham remains a stubborn Hold with no price target, a posture they have maintained for well over a year. The mean price target of $4.00 implies modest upside from current levels — not the kind of gap that fuels a crowded bull thesis. The fundamental backdrop gives shorts ammunition: Q1 revenues fell 8% year-on-year, industrial demand has been soft, and the company's own F-score of 3 and negative Altman Z-score signal ongoing financial stress. The counter-argument — healthcare segment growth of 17% and a $5 million improvement in operating expenses — has not yet moved the needle on profitability.
Institutional flows add a wrinkle. Two Sigma built a position of nearly 5.9 million shares as of late March, adding over 3.3 million in the quarter — one of the largest recent additions among known holders. Marshall Wace increased by 1.4 million shares across the same period. Quant and systematic money flowing in alongside a growing short book is not unusual in a high-short-interest name, but it does mean both sides of the trade are being actively managed by sophisticated players.
The earnings calendar marks the next hard test. After Q1 results in mid-May triggered a 26% one-day spike — itself a short-squeeze-adjacent move — the next print is scheduled for August 10. Between now and then, the question is whether the stock can sustain a price that has outrun its fundamental base, or whether short sellers adding into strength are positioning for a mean reversion that the company's financials make plausible. Availability tightening and cost-to-borrow trends in July will be worth watching closely as the event approaches.
See the live data behind this article on ORTEX.
Open DDD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
